Evidence map›Paper›PMID 20627173›Full record

ArticleNeuroscience2010

Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke.

D C Morris, M Chopp, L Zhang, M Lu, Z G Zhang

Abstract read
In one paragraph

Article in Neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

D C MorrisDepartment of Emergency Medicine, Henry Ford Health Systems, Detroit, MI, USA.
M Chopp
L Zhang
M Lu
Z G Zhang
Henry Ford Health System · USOakland University · US

Funding

PREDICTION OF HUMAN BRAIN INFARCTION BY MRIP01NS023393 · NINDS · HENRY FORD HOSPITAL · PI ZHANG, ZHENG GANG · 1986 to 2011
$11.0M
Treatment of Acute Embolic Stroke with Statins and rt-PAR01HL064766 · NHLBI · HENRY FORD HEALTH SYSTEM · PI ZHANG, ZHENG GANG · 2001 to 2009
$2.4M
Treatment of stroke with a clinically approved proteasome inhibitorR01NS062832 · NINDS · HENRY FORD HEALTH SYSTEM · PI ZHANG, LI · 2008 to 2012
$1.4M
NHLBI NIH HHS R01 HL064766NHLBI NIH HHS R01HL64766NINDS NIH HHS P01 NS023393NINDS NIH HHS P01 NS23393NINDS NIH HHS R01 NS062832
6 · The paper itself

Abstract

unlabelledThymosin beta4 (Tbeta4) is a developmentally expressed 43-amino acid peptide that inhibits organization of the actin-cytoskeleton by sequestration of G-actin monomers. Tbeta4 improves cardiac function after myocardial infarction in adult mice and promotes healing properties in both dermal and corneal wounds. We tested the hypothesis that Tbeta4 improves functional neurological outcome in a rat model of embolic stroke. EXPERIMENTAL PROCEDURES: Male Wistar rats (n=18) were subjected to embolic middle cerebral artery occlusion (MCAo). Tbeta4 (6 mg/kg, IP) was administered 24 h after MCAo and then every 3 days for four additional doses (n=9). Rats treated with saline were used as a control (n=9). The adhesive-removal test (ART) and modified Neurological Severity Score (mNSS) were performed to measure functional outcome. Rats were sacrificed 56 days after MCAo. Immunostaining was performed with antibodies against NG-2 (chondroitin sulfate proteoglycan), CNPase (2", 3"-cyclic nucleotide 3'-phosphodiesterase) to detect immature and mature oligodendrocytes. Neurofilament-H (NF-H) antibodies were used to detect axons while myelinated axons were identified with Bielschowsky/Luxol (B/L) Blue staining. EBA (endothelial barrier antigen) was used for detection of mature vessels.

resultsIschemic rats treated with Tbeta4 demonstrated a significant overall improvement (P<0.01) in the ART and the mNSS when compared to controls. Significant improvement was observed beginning at 14 and 35 days, respectively. Lesion volumes showed no significant differences between the two groups. Treatment with Tbeta4 increased myelinated axons and increased vessel density in the ischemic boundary (P<0.05) and augmented remyelination which was associated with an increase of oligodendrocyte progenitor cells (OPCs) and myelinating oligodendrocytes (P<0.05).

conclusionsThe present study suggests that Tbeta4 improves neurological functional outcome after embolic stroke in rats. Axonal remodeling from mobilization of OPCs is proposed as contributing to Tbeta4 induced functional improvement.

Indexed as

AnimalsAntigensAxonsBasic Helix-Loop-Helix ProteinsCell ProliferationChondroitin Sulfate Proteoglycan 4Corpus CallosumCorpus StriatumInfarction, Middle Cerebral ArteryMaleMyelin SheathNeuronsOligodendrogliaProteoglycansRatsRats, WistarAntigensAscl1 protein, ratBasic Helix-Loop-Helix ProteinsChondroitin Sulfate Proteoglycan 4ProteoglycansThymosinThymosin beta(4)

Identifiers

PMID20627173
PMCPMC2907184
OpenAlexW2077125584

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.